Incidence and outcome of surgical procedures after sirolimus-eluting stent implantation: a report from the j-Cypher registry

Abstract

The incidence of surgical procedures after sirolimus-eluting stent (SES) implantation and, more importantly, the rate of perioperative stent thrombosis (ST) and/or other adverse events have not yet been adequately addressed. The incidence and outcome of the surgical procedures after SES implantation were prospectively evaluated in a large-scale multicenter registry of patients undergoing SES implantation. Among 12,824 patients enrolled in the registry, cumulative incidences of surgical procedures were 0.7% at 60days, 5.1% at 1year and 14.7% at 3years. Surgical procedures were performed in 1,430 patients including non-coronary artery bypass graft (CABG) surgery in 1,275 patients and CABG in 189 patients. The incidences of death/myocardial infarction/ST (definite or probable) and ST (definite or probable) at 30days after surgical procedures were 2.7 and 0.35%, respectively. Surgery performed within 60days after SES implantation as compared with that performed beyond 60days was associated with significantly higher incidences of death/myocardial infarction/ST (definite or probable) and ST (definite or probable) at 30days after surgical procedures (6.4 vs. 2.5%: P=0.02 and 2.2 vs. 0.23%: P=0.002, respectively). Surgery within 60days as well as hemodialysis and small body mass index were independent risk factors of death/myocardial infarction/ST (definite or probable) identified by multivariable analysis. Surgical procedures were required fairly often after SES implantation. The incidences of adverse cardiac events including ST after surgical procedures were acceptably low. Surgery within 60days after SES implantation carried significantly higher risks as compared with those beyond 60days.